高剂量的多菌株Bacillus益生菌增强治疗,并通过免疫和微生物群调节减少持续腹的儿童的抗生素使用
Ha Thuy Dang1, Thuy Thi Bich Phung2, Dien Minh Tran3
1Department of Gastroenterology, Vietnam National Children's Hospital, No. 18/879 Lathanh, Lang, Hanoi, Vietnam.
Scientific reports
|August 18, 2025
概括
高剂量的Bacillus子益生菌显著缩短了儿童持续性腹的恢复时间3天. 这种益生菌干预还使抗生素使用减少了25%,并改善了肠道微生物群的组成.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 持续性腹是儿科护理中的一个重大临床挑战.
- 目前针对持续性腹的治疗干预措施通常在有效性和副作用方面存在局限性.
研究的目的:
- 评估高剂量多菌株细菌子益生菌 (LiveSpo DIA30) 作为儿童持续性腹的辅助治疗的有效性.
- 评估细菌子对恢复时间,抗生素使用,炎症标志物和肠道微生物群组成的影响.
主要方法:
- 进行了一项随机,双盲,受控的临床试验.
- 参与者接受了细菌子益生菌 (LiveSpo DIA30) 或安慰剂.
- 结果包括恢复期,疗效,抗生素持续时间,促炎性细胞因子,便sIgA和16S rRNA元基因组分析.
主要成果:
- 细菌子显著缩短了3天的恢复时间,并提高了1.60倍的疗效 (p < 0.0001).
- 在益生菌组中,抗生素治疗持续时间减少了2天 (25%的减少).
- 益生菌降低了促炎性细胞因子 (IL-17,IL-23,TNF-α) 和调节了肠道微生物群,增加了有益的细菌,减少了像Escherichia fergusonii这样的有害物种.
结论:
- 高剂量,多菌株的Bacillus子益生菌在迅速缓解儿童持续性腹症状方面是有效的.
- 这种益生菌干预改善了原生肠道微生物群,并调节了免疫反应,从而减少了对抗生素的依赖.
- 这项研究提供了强有力的临床和实验室证据,支持细菌子用于儿科持续性腹管理.
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
203
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
203
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Microorganisms in Medicine and Therapeutics
314
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
314
Drugs for Treatment of Constipation-Predominant IBS
331
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
331
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419


